Skip to main content

DiagnoCure Laboratory Gets New York Permit

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure has received a Clinical Laboratory Permit from New York State regulators for its CLIA-approved and CAP-certified laboratory, the company announced today.

The permit from the New York State Department of Health allows DiagnoCure's lab in West Chester, Penn., to use the company's Previstage GCC Colorectal Staging Test on commercial samples originating in New York, which could crack open a significant market for the test, DiagnoCure said in a statement.

Citing the American Cancer Society, the company said that New York has the third-highest rate of new colorectal cancer cases among states in the US.

"This license, coupled with the rollout of our colorectal cancer disease management program, is a considerable milestone in bringing our proprietary Previstage GCC test to colorectal specialists nationwide," said Valerie Palmieri, president of DiagnoCure Oncology Laboratories, in the company's statement.

She added the test is the only molecular test available to help better identify whether colorectal cancer has spread to the lymph nodes. The test received CLIA certification in 2008. In New York State, however, a CLIA-approved test must also receive clearance from state regulators for use.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.